Lipidomics Reveals Altered Biosynthetic Pathways of Glycerophospholipids and Cell Signaling As Biomarkers of the Polycystic Ovary Syndrome

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Feb 14

PMID 29435121

Citations 16

Authors

Mariona Jove

Irene Pradas

Alba Naudi

Susana Rovira-Llopis

Celia Banuls

Milagros Rocha

Manuel Portero-Otin

Antonio Hernandez-Mijares

Victor M Victor

Reinald Pamplona

Affiliations

Soon will be listed here.

Abstract

Purpose: In this work, a non-targeted approach was used to unravel changes in the plasma lipidome of PCOS patients. The aim is to offer new insights in PCOS patients strictly selected in order to avoid confounding factors such as dyslipemia, obesity, altered glucose/insulin metabolism, cardiovascular disease, or cancer.

Results: Multivariate statistics revealed a specific lipidomic signature for PCOS patients without associated pathologies. This signature implies changes, mainly by down-regulation, in glycerolipid, glycerophospholipid and sphingolipid metabolism suggesting an altered biosynthetic pathway of glycerophospholipids and cell signaling as second messengers in women with PCOS.

Conclusions: Our study confirms that a lipidomic approach discriminates a specific phenotype from PCOS women without associated pathologies from healthy controls.

Methods: In a cross-sectional pilot study, data were obtained from 34 subjects, allocated to one of two groups: a) lean, healthy controls ( = 20), b) PCOS patients ( = 14) with diagnosis based on hyperandrogenaemia, oligo-anovulation and abnormal ovaries with small follicular cysts. A detailed biochemical characterization was made and lipidomic profiling was performed via an untargeted approach using LC-ESI-QTOF MS/MS.

Citing Articles

Screening of serum biomarkers in patients with PCOS through lipid omics and ensemble machine learning.

Chen J, Chen W, Zhu Z, Xu S, Huang L, Tan W PLoS One. 2025; 20(1):e0313494.

PMID: 39775242 PMC: 11706364. DOI: 10.1371/journal.pone.0313494.

Use of Olives-derived Phytochemicals for Prevention and Treatment of Atherosclerosis: An Update.

Dabravolski S, Pleshko E, Sukhorukov V, Glanz V, Sobenin I, Orekhov A Curr Top Med Chem. 2024; 24(25):2173-2190.

PMID: 39162269 DOI: 10.2174/0115680266314560240806101445.

High levels of fatty acid-binding protein 5 excessively enhances fatty acid synthesis and proliferation of granulosa cells in polycystic ovary syndrome.

Liu J, Li J, Wu X, Zhang M, Yan G, Sun H J Ovarian Res. 2024; 17(1):44.

PMID: 38373971 PMC: 10875862. DOI: 10.1186/s13048-024-01368-6.

The Implication of Mechanistic Approaches and the Role of the Microbiome in Polycystic Ovary Syndrome (PCOS): A Review.

Mukherjee A, Wanjari U, Kannampuzha S, Murali R, Namachivayam A, Ganesan R Metabolites. 2023; 13(1).

PMID: 36677054 PMC: 9863528. DOI: 10.3390/metabo13010129.

Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach.

Dahabiyeh L, Mujammami M, AlMalki R, Arafat T, Benabdelkamel H, Alfadda A Int J Mol Sci. 2022; 23(19).

PMID: 36232780 PMC: 9569788. DOI: 10.3390/ijms231911478.

References

Glueck C, Morrison J, Goldenberg N, Wang P . Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism. 2009; 58(5):714-21. DOI: 10.1016/j.metabol.2009.02.005. View

Galazis N, Pang Y, Galazi M, Haoula Z, Layfield R, Atiomo W . Proteomic biomarkers of endometrial cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration. Gynecol Endocrinol. 2013; 29(7):638-44. DOI: 10.3109/09513590.2013.777416. View

Cotrozzi G, MATTEINI M, Relli P, Lazzari T . Hyperinsulinism and insulin resistance in polycystic ovarian syndrome: a verification using oral glucose, I.V. Glucose and tolbutamide. Acta Diabetol Lat. 1983; 20(2):135-42. DOI: 10.1007/BF02624914. View

Castro-Perez J, Kamphorst J, DeGroot J, Lafeber F, Goshawk J, Yu K . Comprehensive LC-MS E lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J Proteome Res. 2010; 9(5):2377-89. DOI: 10.1021/pr901094j. View

Azziz R . Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril. 2005; 83(5):1343-6. DOI: 10.1016/j.fertnstert.2005.01.085. View

Zhao H, Zhao Y, Li T, Li M, Li J, Li R . Metabolism alteration in follicular niche: The nexus among intermediary metabolism, mitochondrial function, and classic polycystic ovary syndrome. Free Radic Biol Med. 2015; 86:295-307. DOI: 10.1016/j.freeradbiomed.2015.05.013. View

Sun L, Hu W, Liu Q, Hao Q, Sun B, Zhang Q . Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res. 2012; 11(5):2937-46. DOI: 10.1021/pr3000317. View

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2008; 91(2):456-88. DOI: 10.1016/j.fertnstert.2008.06.035. View

Zhao Y, Fu L, Li R, Wang L, Yang Y, Liu N . Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med. 2012; 10:153. PMC: 3599233. DOI: 10.1186/1741-7015-10-153. View

10.

Carmina E, Lobo R . Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999; 84(6):1897-9. DOI: 10.1210/jcem.84.6.5803. View

11.

Moran L, Mundra P, Teede H, Meikle P . The association of the lipidomic profile with features of polycystic ovary syndrome. J Mol Endocrinol. 2017; 59(1):93-104. DOI: 10.1530/JME-17-0023. View

12.

Legro R, Driscoll D, Strauss 3rd J, Fox J, Dunaif A . Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998; 95(25):14956-60. PMC: 24557. DOI: 10.1073/pnas.95.25.14956. View

13.

Escobar-Morreale H . Polycystic ovary syndrome: treatment strategies and management. Expert Opin Pharmacother. 2008; 9(17):2995-3008. DOI: 10.1517/14656560802559932. View

14.

Dunaif A . Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6):774-800. DOI: 10.1210/edrv.18.6.0318. View

15.

Alvarez-Blasco F, Botella-Carretero J, San Millan J, Escobar-Morreale H . Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006; 166(19):2081-6. DOI: 10.1001/archinte.166.19.2081. View

16.

Victor V, Rocha M, Banuls C, Sanchez-Serrano M, Sola E, Gomez M . Mitochondrial complex I impairment in leukocytes from polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2009; 94(9):3505-12. DOI: 10.1210/jc.2009-0466. View

17.

Barry J, Azizia M, Hardiman P . Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014; 20(5):748-58. PMC: 4326303. DOI: 10.1093/humupd/dmu012. View

18.

Wang W, Wang S, Tan S, Wen M, Qian Y, Zeng X . Detection of urine metabolites in polycystic ovary syndrome by UPLC triple-TOF-MS. Clin Chim Acta. 2015; 448:39-47. DOI: 10.1016/j.cca.2015.06.008. View

19.

Kosova G, Urbanek M . Genetics of the polycystic ovary syndrome. Mol Cell Endocrinol. 2012; 373(1-2):29-38. PMC: 3609918. DOI: 10.1016/j.mce.2012.10.009. View

20.

Sana T, Roark J, Li X, Waddell K, Fischer S . Molecular formula and METLIN Personal Metabolite Database matching applied to the identification of compounds generated by LC/TOF-MS. J Biomol Tech. 2009; 19(4):258-66. PMC: 2567134. View